Under the agreement, Mirada’s RegEngine image registration algorithms will be integrated into the RefleXion X1 treatment planning software
RefleXion Medical signs licensing agreement with Mirada Medical. (Credit: Colin Behrens from Pixabay)
Therapeutic oncology company RefleXion Medical has signed a non-exclusive, worldwide licensing agreement with Mirada Medical to advance personalised cancer treatment.
Under the agreement, Mirada’s RegEngine image registration algorithms will be integrated into the RefleXion X1 treatment planning software.
The algorithms line up the patient’s anatomy between several imaging modalities or between radiotherapy treatments.
RefleXion chief business officer Thorsten Melcher said: “Day-of-treatment modifications, called adaptive radiotherapy, are critical for responding to changes in patient anatomy that occur as a result of cancer treatment, and to lowering toxicity to improve outcomes.
“In challenging patients, such as those with metastatic disease where more than one tumour may be treated, adaptation requires robust tools such as Mirada’s sophisticated RegEngine software, so that clinicians can quickly assess patient anatomy and, in the future their biology, to implement changes to the treatment plan.
“Mirada’s extensive industry experience and development expertise were key factors in our decision to pursue this agreement.”
RefleXion said that image registration is a challenging set of algorithms that lines up the anatomical pictures of a patient obtained at various points in time and with several imaging modalities.
Registration of the tumour target to be treated as well as adjacent anatomy to avoid is crucial in radiation oncology, where millimetres matter to protect healthy tissue.
BgRT (biology-guided radiotherapy) is intended to overcome the technical limits of current radiation techniques by leveraging a PET radiotracer to develop a unified motion management system for tumours.
BgRT delivers a monitored radiation dosage to the malignancy using real-time biological data.
The integration of RegEngine into BgRT will enable doctors to quickly adapt the daily treatment plan by accurately registering pictures and image components necessary for treatment planning and dosage calculation.
RegEngine warps or deforms the images pixel by pixel, a process called deformable image registration to assist clinicians in accounting for these changes from biological processes.
Mirada CEO Jon DeVries said: “Our relationship with RefleXion is another example of our ability to work with cutting edge oncology companies.
“RefleXion’s biology-guided radiotherapy has the potential to offer a new treatment option for patients with all stages of cancer, and we are excited and proud to have RegEngine selected as a key component of the treatment planning process in this exciting novel technology.”